Malignancy Risks of Neurokinin Receptor Antagonists

EP: 1.Overview of KNDy neurons

EP: 2.VMS Symptoms and Neurokinin Receptor Antagonists

EP: 3.Neurokinin and Estrogen Balance in Menopausal Hot Flashes for Primary Care

EP: 4.Fezolinetant Guidelines and Emerging Data on Menopause and Liver Health

EP: 5.Molecular Comparison and Safety Profiles of Fezolinetant and Elinzanetant

Now Viewing

EP: 6.Malignancy Risks of Neurokinin Receptor Antagonists

EP: 7.Guidance for PCPs: Streamlining Menopause Care

EP: 8.Nonestrogen Treatments for Menopause

EP: 9.VMS Treatment Guidelines

What does data from the clinical trials suggest about the incidence of neoplasms with fezolinetant and elinzanetant?

Notes:Across 3 clinical trials, fezolinetant is associated with a small, but higher incidence of endometrial hyperplasia or endometrial malignancy.

There were no cases of endometrial hyperplasia or endometrial malignancy observed with elinzanetant in a long-term safety study.